Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: Developmental toxicity

Carles Cristòfol, Marc Navarro, Carme Franquelo, Josep Enric Valladares, Ana Carretero, Jesus Ruberte, Margarita Arboix

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)


Netobimin (NTB), a benzimidazole prodrug with a good anthelmintic spectrum, was administered orally to female rats at a dose of 59.5 mg NTB/kg, to study its pharmacokinetic behavior and the disposition of its most important metabolites, albendazole (ABZ), albendazole sulfoxide (ABZSO), and albendazole sulfone (ABZSO2). ABZ was found in plasma after 6 hr. Peak plasma concentrations (C(max)) and areas under curves (AUC) of ABZSO were eight- and fourfold higher, respectively, than those of ABZSO2. To study NTB disposition in pregnant rats, three different drug doses (50, 59.5, and 70.7 mg/kg) were given. No significant differences were found between plasma concentrations for each metabolite at the three doses studied. Only ABZ concentrations rose slightly as dose increased. ABZ, ABZSO, and ABZSO2 were found in amniotic sacs and embryos at concentrations that were higher than plasma at the same times. The fetuses obtained after administration of each of the doses of NTB were studied to detect developmental toxicity. A significant correlation was found between rate of developmental toxicity and metabolite concentration. ABZSO embryo concentrations could be the main factor accounting for toxicity.
Original languageEnglish
Pages (from-to)56-61
JournalToxicology and Applied Pharmacology
Publication statusPublished - 1 Jan 1997


Dive into the research topics of 'Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: Developmental toxicity'. Together they form a unique fingerprint.

Cite this